Skip to main content
Companion Care
Regulatory & Legal Dossier — Counsel & Clinical-Director Facing

Boojee Companion Care
Regulatory & Legal Analysis

An honest, cited assessment of the regulatory perimeter for a wellness-tier conversational AI companion that screens with validated instruments (UCLA-3, PHQ-2, PHQ-9, GAD-7), monitors trends, escalates to humans, and surfaces 988 on crisis. Covers FDA / Software-as-a-Medical-Device classification, unlicensed practice of medicine and psychology, the 2025–2026 AI-therapy statutes, crisis duty-to-warn and mandatory reporting, contract/liability exposure, and AI-specific law (Colorado, EU AI Act, FTC).

Audience
Outside regulatory/FDA counsel; licensed clinical director; health-plan medical & compliance officers
Posture
Assesses how to be compliant — never asserts that it is
Status
DRAFT-1 · 2026-07-15 · Pending outside counsel review
Frame
Stay-in-lane design for the wellness / non-device space — what keeps us there and what breaks it

Section 1 · Doc A · regulatory-analysis.md

FDA / Software-as-a-Medical-Device — staying in the general-wellness / non-device lane

The 21st Century Cures Act (2016) added FD&C Act §520(o), carving certain software functions out of the "device" definition. Two carve-outs apply here, and we design to satisfy both:

  • §520(o)(1)(B) — general-wellness software: intended for maintaining/encouraging a healthy lifestyle and unrelated to the diagnosis, cure, mitigation, prevention, or treatment of a disease. Basis for framing loneliness/mood check-ins as wellness.
  • §520(o)(1)(E) — Clinical Decision Support (CDS): non-device if it meets all four criteria (below). This is our backstop for the depression/anxiety instruments, which name recognized conditions.

FDA re-issued both interpreting guidances in early 2026, superseding the 2019 (General Wellness) and 2022 (CDS) versions. Commentary reads the 2026 revisions as broadening the non-device space, while stressing that "black-box" algorithmic output remains a device risk and that transparency of inputs/logic is expected — which favors our design.

The four CDS non-device criteria (§520(o)(1)(E)) — all required

  • Criterion 1. Not intended to acquire/process/analyze a medical image, IVD signal, or a pattern/signal from a signal-acquisition system. We take self-reported questionnaire answers only.
  • Criterion 2. Intended to display/analyze medical information about a patient (or reference guidelines). We display the instrument's own published band.
  • Criterion 3. Intended to support/provide recommendations to a health care professional on prevention/diagnosis/treatment. Output routes to the licensed reviewer.
  • Criterion 4. Intended to let the HCP independently review the basis so they do not rely primarily on the software. We show items, raw answers, published algorithm, and citation.
Load-bearing feature Criterion 4 is the one most products fail. Ours is designed to pass it: the reviewer can reconstruct every score by hand. This transparency is simultaneously our FDA argument, our Colorado-AI-Act oversight argument, and our FTC-substantiation argument.

The PHQ-9 item-9 / crisis feature — surface, don't assess

Automated suicide-risk prediction is exactly the black-box clinical decision that reads as a device and forfeits criterion 4. So we do not compute a risk score. PHQ-9 item 9 > 0 (or self-harm language) is a trigger to surface 988 + connect a human — a safety net, explicitly not a risk assessment. The structured assessment (C-SSRS / Columbia Protocol) stays with the human clinician.

Features and claims that would tip us into device territory

  • Diagnostic language — labeling the person with a condition or code.
  • Treatment recommendations — therapy, medication, dose, "start therapy for X."
  • A proprietary/black-box risk score — especially a homegrown suicide-risk model (forfeits criterion 4).
  • Autonomous / time-critical clinical decisions the user acts on without a human ("you're safe, no action needed").
  • Image / IVD / physiologic or affect-signal analysis (voice-stress, facial affect) — forfeits criterion 1, reads as SaMD.
  • Efficacy or clearance claims — "FDA-cleared," "clinically proven to reduce depression," "treats loneliness." Claims set intended use.

Section 2 · Doc B · practice-of-medicine.md

Practice of Medicine & AI-Therapy Laws — the line between wellness support and diagnosis/therapy

Every state licenses the practice of medicine and psychology and prohibits doing either unlicensed (in New York, unlicensed practice of psychology is a felony). The definitions turn on diagnosing and treating. Our product screens, monitors, engages, and routes to licensed humans — the wellness / peer-support side of the line. It never diagnoses or generates a treatment plan.

Live cautionary case — Character.AI The Pennsylvania AG has charged Character.AI with the unlicensed practice of medicine for chatbots that portrayed themselves as licensed physicians and engaged in diagnosis/treatment. The rule for us is direct: never role-play or imply the companion is a licensed clinician.

The 2025–2026 AI-therapy / AI-companion statutes

  • Illinois — WOPR Act (HB 1806), Aug. 2025: bans AI-delivered therapy unless a licensed professional is in charge; bars AI diagnoses/treatment plans; fines to $10,000. Exempts peer support, self-help, and educational resources — the exemption we map to.
  • Nevada — AB 406 (Jul. 2025): bars AI from standing in for a counselor/psychologist; fines to $15,000.
  • Utah — HB 452 (Mar. 2025): permits with AI-disclosure, no data sale, marketing limits, and a safe harbor — a national compliance floor to adopt.
  • New York — AI Companion Models law (eff. Nov. 5, 2025): requires clear/periodic "you're talking to AI" disclosure and crisis-detection → 988 referral; AG enforcement, up to $15,000/day; no private right of action.
  • California — SB 243 (core eff. Jan. 1, 2026): similar companion-safety duties plus a private right of action — materially higher litigation risk.
Disclosure is mandatory Across UT / NY / CA (and the theory of the PA action) the AI must clearly and periodically disclose it is AI, not a human, and not a licensed clinician — and, for a vulnerable senior population, do so in repeated plain language. Our design already surfaces 988 on crisis, which aligns us architecturally with the NY/CA companion laws.

Structural protections: a named licensed clinical director owning clinical judgment (positive screens route to that human); and, before contracting clinicians, a counsel-designed friendly-PC / MSO structure to address the corporate-practice-of-medicine doctrine.

Section 3 · Doc C · crisis-duty-liability.md

Crisis, Duty-to-Warn & Liability — making the crisis pathway defensible

Tarasoff duty to warn / protect

Classic Tarasoff attaches to a licensed professional–patient relationship and a serious danger to an identifiable third party. Most AI self-harm content is diffuse with no identifiable third-party victim, so the classic trigger often won't fire on the AI itself — but the duty can attach to our clinician the moment an escalation reaches them. The SOP must separate (a) self-harm (surface 988 + notify consented caregiver + queue a human alert) from (b) credible threat to an identifiable third party (may trigger the clinician's state duty-to-protect).

Mandatory elder-abuse reporting — a senior-care product's special exposure

Elder-abuse reporting laws sweep broadly: caretakers and persons in a position of trust are commonly mandated reporters, and self-neglect is a reportable category in most states, filed to Adult Protective Services, usually immediately. Whether Boojee's clinical/care staff become mandated reporters in a given state is an open question counsel must resolve — and the SOP must include an elder-abuse / self-neglect reporting pathway with per-state APS routing.

Suicide-risk standard of care — the case law

The high-consequence failure is the response: missed crisis, delayed escalation, or false reassurance. Garcia v. Character Technologies lets a wrongful-death suit proceed on product-liability (failure-to-warn / design-defect) and deceptive-practices theories — including that the bot implied it was a real person / licensed professional. Defensive design: always escalate, never false-reassure, fail loud, log everything, never let the AI make the safety call.

The escalation SOP must contain

  • Enumerated triggers with separate self-harm / third-party-threat / elder-abuse branches.
  • Immediate automated response (surface 988 call/text; consented caregiver notice; never minimize).
  • Named responsible humans, backup/on-call, and explicit after-hours coverage for a 24/7 population.
  • A stated response-time SLA with escalation if unmet.
  • A duty-to-warn branch and an APS-reporting branch.
  • Fail-safe behavior if escalation infra is down; append-only documentation; up-front informed consent; periodic drills/audits.
988 handoff — warm, not cold 988 field standards favor active engagement and warm hand-off. The companion should stay present through the handoff, offer 988 call + text, offer consented caregiver notification, and not attempt clinical de-escalation itself — connect and stay warm, then hand off.

Liability & insurance (high level)

Exposures: missed crisis, false reassurance, over-reliance by isolated seniors (the exact concern behind the FTC 6(b) companion inquiry and the NY/CA laws), data breach, and misrepresentation. Mitigate with escalate-always design, repeated "not a substitute for people/professional care" disclosure, informed consent, and claims discipline. Limitation-of-liability clauses are frequently unenforceable against wrongful-death / gross-negligence / consumer-protection claims — they reduce but do not eliminate exposure. Carry tech E&O, professional liability (E&O), general liability, and cyber — and confirm policies do not exclude AI-driven harm, suicide/mental-health claims, or bodily-injury-from-software.

Section 4 · Doc D · ai-law.md

AI-Specific & Cross-Cutting Law — Colorado · EU AI Act · FTC · Telehealth

Colorado AI Act (SB 24-205 → SB 26-189)

Duties on deployers of high-risk AI making consequential healthcare decisions: reasonable care against algorithmic discrimination, impact assessments, disclosures, human oversight. Original Feb. 1, 2026 date was postponed; the repeal-and-reenact (SB 26-189) is effective Jan. 1, 2027. A carve-out exists for HIPAA-covered entities whose AI recommendations require a provider to act. Counsel to confirm our deployer status; our human-in-the-loop design aligns with the carve-out logic.

EU AI Act — only if we serve the EU

Health-AI is high-risk where the AI is or is a safety component of an MDR/IVDR-classified medical device — the AI-Act tier is tied to the device class. Because we design to stay a non-device, the parallel EU argument is that we are not high-risk on that ground — but this must be re-run under EU MDR (its device definition differs). Article 50 still requires AI-interaction disclosure, and adding emotion recognition would attach its own transparency duty — another reason not to add affect inference. (High-risk deadlines are being pushed toward Dec. 2027 / Aug. 2028, subject to pending legislation.)

FTC — deceptive AI claims + Health Breach Notification Rule

The FTC's "Operation AI Comply" targets unsubstantiated AI claims (it settled with Pieces Technologies over overstated clinical-AI accuracy). Any diagnostic-accuracy / "AI clinician" / efficacy claim must be substantiated or not made — our honesty posture (instruments validated, product not; no clearance) is the FTC-safe stance. Separately, the 2024 Health Breach Notification Rule amendments (eff. Jul. 29, 2024) extend it to many non-HIPAA health apps.

Two breach regimes With no BAA yet, we are likely on the FTC HBNR track for any real consumer health data today; once the HIPAA BAA is executed, the HITECH breach rule governs instead. Counsel/privacy track must pin which regime applies at each stage — they have different triggers and timelines.

Telehealth / scope

The AI (screen / monitor / connect) should sit outside telehealth regulation. The human escalation layer — when a licensed clinician engages an enrollee remotely — is telehealth and pulls in licensure-by-enrollee-state, telehealth consent, and standard-of-care for that clinician. Build that layer to telehealth norms.

Section 5 · Consolidated

Compliance Checklist — stay-legal requirements & tripwires

Design and claims constraints we hold ourselves to. This is a self-imposed posture, not an FDA determination or compliance certification. A reviewer can instantly see what keeps us in the wellness lane and what would break it.

DO — required practice DON'T — hard tripwire; breaks the carve-out
Type Requirement / Tripwire Rationale
DO No diagnosis, no treatment plans to the user — ever.
Never label a condition; never recommend therapy/meds/dose.
Defines the wellness side of the UPM line
DON'T No proprietary/black-box risk score.
Especially no homegrown suicide-risk model. Only published instruments' own bands, with citation.
Forfeits CDS criterion 4; may tip to SaMD
DO Full transparency for the human reviewer.
Items, raw answers, published algorithm, source citation — reviewer reconstructs score by hand.
Criterion 4; Colorado AI Act; FTC substantiation
DO Self-report only — no images, IVD signals, or physiologic/affect-signal analysis.
No voice-stress, no facial affect inference.
Preserves CDS criterion 1; avoids EU emotion-recognition duty
DO Human-in-the-loop by design.
Positive screens route to a licensed human; AI never closes the clinical loop or makes a time-critical call.
IL WOPR; Colorado AI Act carve-out alignment
DO Crisis feature = surface 988 + a human.
Explicitly labeled "not a suicide-risk assessment." Escalate always; never false-reassure; fail loud; log everything.
Garcia; NY/CA companion laws; 988 warm-handoff standard
DO Clear, periodic "I'm AI, not a human, not a licensed clinician" disclosure.
Repeated in plain language — mandatory for a senior population.
UT / NY / CA statutes; PA UPM theory; EU Art. 50
DO Stay inside the peer-support / self-help / educational exemption in behavior and marketing. IL WOPR Act safe harbor
DON'T Claims discipline — no "FDA-cleared," "clinically proven," "treats," "diagnoses," "cures," or "AI clinician."
Market as: screen / monitor / connect.
Claims set intended use; FTC Operation AI Comply
DON'T No sale of intimate mental-health data.
Strong privacy + breach posture.
UT safe-harbor condition; FTC HBNR / HIPAA
DO Appoint a named licensed clinical director + written escalation SOP before any real enrollment. IL WOPR; duty-to-warn; UPM defense
DO Maintain a 50-state operating map and re-check as new AI-therapy bills pass. Rapidly evolving state statute landscape
DO Confirm insurance: tech E&O, professional E&O, cyber — no AI/suicide/software-bodily-injury exclusions. Garcia product-liability theory; data-breach exposure

Section 6 · Honesty Commitment

Honest Gaps — open items & unresolved risks

These are open items and unresolved risks. Stating them is load-bearing; they are not resolved by this dossier. They constitute the roadmap for counsel and the clinical director.

Open — not resolved by this dossier
What is not yet true
Each item below is a gap with a clear owner and action. They are presented as a roadmap, not a concession.
  • ! No licensed clinical director is appointed yet — increasingly the condition of legality under the new laws, not merely best practice. Our #1 disclosed gap.
  • ! No written escalation SOP exists yet — the highest-priority defensibility gap; must be authored/owned by the clinical director.
  • ! Mandated-reporter status is undetermined per state for elder abuse / neglect / self-neglect; no APS reporting pathway is documented.
  • ! After-hours / on-call crisis coverage is undefined — a 24/7 population with a business-hours human queue is a serious gap.
  • ! No E&O / professional-liability / cyber insurance confirmed in force.
  • ! HIPAA BAA not yet executed — governing breach regime (FTC HBNR vs. HITECH) is unsettled until it is.
  • ! CDS carve-out for a consumer/senior-facing tool is untested by us — the guidance is written around clinician-facing software; counsel must confirm the theory holds where the "HCP" is a downstream care manager.
  • ! The 2026 FDA guidance text should be verified against primary source (not only secondary summaries) before the intended-use statement is finalized. No FDA pre-submission / 513(g) is on file.
  • ! No maintained 50-state AI-therapy operating matrix; CPOM contracting structure unresolved.
  • ! Conversational-content governance is needed so the companion doesn't drift into therapy-like advice in practice (which would forfeit the exemptions).
  • ! Crisis-language detection accuracy (false-negatives = missed crises) is itself safety-critical and needs validation + monitoring.
  • ! EU exposure is dormant (U.S.-targeted); if we expand, a fresh EU-MDR + GDPR analysis is required — the U.S. wellness conclusion does not import.

Section 7 · Citations

Primary & Secondary Sources